Central Nervous System

Biotech AltPep scores around $53m in Series B funding round

US-based amyloid diseases treatment solutions developer AltPep has raised $52.9m in its Series B investment round led by Senator Investment Group.

Ractigen receives orphan drug designation for ALS therapy

Ractigen Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for its new therapeutic siRNA, RAG-17, to treat Amyotrophic Lateral Sclerosis (ALS).

Ryne Biotechnology receives CIRM grant to advance RNDP-001

Ryne Biotechnology has received a $4m Clinical Stage Research Program (CLIN1) grant from the California Institute for Regenerative Medicine (CIRM) to advance its lead candidate RNDP-001.

Astex, MDI announce collaboration to identify neurodegenerative disease drugs

Astex and Cardiff University Medicines Discovery Institute (MDI) have announced a multi-year research collaboration which is aimed at identifying new drugs for the treatment of neurodegenerative diseases.

EMA accepts Eisai, Biogen’s lecanemab MAA for review to treat AD

The European Medicines Agency (EMA) has accepted for review Eisai and Biogen’s marketing authorization application (MAA) submitted for lecanemab to treat early Alzheimer’s disease (AD).

Eisai submits marketing authorization application for AD therapy in Japan

Eisai has submitted a marketing authorization application to the Pharmaceuticals and Medical Devices Agency (PMDA) for investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab for early Alzheimer’s Disease (AD) in Japan.

FDA accepts review of Biohaven’s NDA for zavegepant nasal spray

The US Food and Drug Administration (FDA) has accepted review of a new drug application (NDA) filed by Biohaven Pharmaceutical for zavegepant nasal spray.

GNS and Arvinas partner for neurodegenerative disease drug development

GNS Healthcare and Arvinas have entered into a collaboration for generating insights to help expedite neurodegenerative disease drug development.

Roche signs strategic collaboration and licence agreement with Roche

Shape Therapeutics has entered into a multi-target strategic collaboration and licence agreement with Roche to develop gene therapy for particular targets in the areas of Alzheimer’s disease, Parkinson’s disease, and rare diseases.